List of Contents

Immunotherapy Drugs Market Size, Share, and Trends 2024 to 2034

The global immunotherapy drugs market size accounted for USD 270.2 billion in 2024, grew to USD 318.83 billion in 2025 and is projected to surpass around USD 1,414.16 billion by 2034, representing a healthy CAGR of 18% between 2024 and 2034. The North America immunotherapy drugs market size is calculated at USD 124.29 billion in 2024 and is expected to grow at a fastest CAGR of 18.12% during the forecast year.

  • Last Updated : October 2024
  • Report Code : 1472
  • Category : Healthcare

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Immunotherapy Drugs Market 

5.1. COVID-19 Landscape: Immunotherapy Drugs Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Immunotherapy Drugs Market, By Drug

8.1. Immunotherapy Drugs Market, by Drug Type, 2024-2034

8.1.1. Monoclonal Antibodies

8.1.1.1. Market Revenue and Forecast (2021-2034)

8.1.2. Vaccines

8.1.2.1. Market Revenue and Forecast (2021-2034)

8.1.3. Interleukins

8.1.3.1. Market Revenue and Forecast (2021-2034)

8.1.4. Interferons Alpha & Beta

8.1.4.1. Market Revenue and Forecast (2021-2034)

8.1.5. Others

8.1.5.1. Market Revenue and Forecast (2021-2034)

Chapter 9. Global Immunotherapy Drugs Market, By Therapeutic Area

9.1. Immunotherapy Drugs Market, by Therapeutic Area, 2024-2034

9.1.1. Cancer

9.1.1.1. Market Revenue and Forecast (2021-2034)

9.1.2. Infectious Diseases

9.1.2.1. Market Revenue and Forecast (2021-2034)

9.1.3. Autoimmune & Inflammatory Diseases

9.1.3.1. Market Revenue and Forecast (2021-2034)

9.1.4. Others

9.1.4.1. Market Revenue and Forecast (2021-2034)

Chapter 10. Global Immunotherapy Drugs Market, Regional Estimates and Trend Forecast

10.1. North America

10.1.1. Market Revenue and Forecast, by Drug (2021-2034)

10.1.2. Market Revenue and Forecast, by Therapeutic Area (2021-2034)

10.1.3. U.S.

10.1.3.1. Market Revenue and Forecast, by Drug (2021-2034)

10.1.3.2. Market Revenue and Forecast, by Therapeutic Area (2021-2034)

10.1.4. Rest of North America

10.1.4.1. Market Revenue and Forecast, by Drug (2021-2034)

10.1.4.2. Market Revenue and Forecast, by Therapeutic Area (2021-2034)

10.2. Europe

10.2.1. Market Revenue and Forecast, by Drug (2021-2034)

10.2.2. Market Revenue and Forecast, by Therapeutic Area (2021-2034)

10.2.3. UK

10.2.3.1. Market Revenue and Forecast, by Drug (2021-2034)

10.2.3.2. Market Revenue and Forecast, by Therapeutic Area (2021-2034)

10.2.4. Germany

10.2.4.1. Market Revenue and Forecast, by Drug (2021-2034)

10.2.4.2. Market Revenue and Forecast, by Therapeutic Area (2021-2034)

10.2.5. France

10.2.5.1. Market Revenue and Forecast, by Drug (2021-2034)

10.2.5.2. Market Revenue and Forecast, by Therapeutic Area (2021-2034)

10.2.6. Rest of Europe

10.2.6.1. Market Revenue and Forecast, by Drug (2021-2034)

10.2.6.2. Market Revenue and Forecast, by Therapeutic Area (2021-2034)

10.3. APAC

10.3.1. Market Revenue and Forecast, by Drug (2021-2034)

10.3.2. Market Revenue and Forecast, by Therapeutic Area (2021-2034)

10.3.3. India

10.3.3.1. Market Revenue and Forecast, by Drug (2021-2034)

10.3.3.2. Market Revenue and Forecast, by Therapeutic Area (2021-2034)

10.3.4. China

10.3.4.1. Market Revenue and Forecast, by Drug (2021-2034)

10.3.4.2. Market Revenue and Forecast, by Therapeutic Area (2021-2034)

10.3.5. Japan

10.3.5.1. Market Revenue and Forecast, by Drug (2021-2034)

10.3.5.2. Market Revenue and Forecast, by Therapeutic Area (2021-2034)

10.3.6. Rest of APAC

10.3.6.1. Market Revenue and Forecast, by Drug (2021-2034)

10.3.6.2. Market Revenue and Forecast, by Therapeutic Area (2021-2034)

10.4. MEA

10.4.1. Market Revenue and Forecast, by Drug (2021-2034)

10.4.2. Market Revenue and Forecast, by Therapeutic Area (2021-2034)

10.4.3. GCC

10.4.3.1. Market Revenue and Forecast, by Drug (2021-2034)

10.4.3.2. Market Revenue and Forecast, by Therapeutic Area (2021-2034)

10.4.4. North Africa

10.4.4.1. Market Revenue and Forecast, by Drug (2021-2034)

10.4.4.2. Market Revenue and Forecast, by Therapeutic Area (2021-2034)

10.4.5. South Africa

10.4.5.1. Market Revenue and Forecast, by Drug (2021-2034)

10.4.5.2. Market Revenue and Forecast, by Therapeutic Area (2021-2034)

10.4.6. Rest of MEA

10.4.6.1. Market Revenue and Forecast, by Drug (2021-2034)

10.4.6.2. Market Revenue and Forecast, by Therapeutic Area (2021-2034)

10.5. Latin America

10.5.1. Market Revenue and Forecast, by Drug (2021-2034)

10.5.2. Market Revenue and Forecast, by Therapeutic Area (2021-2034)

10.5.3. Brazil

10.5.3.1. Market Revenue and Forecast, by Drug (2021-2034)

10.5.3.2. Market Revenue and Forecast, by Therapeutic Area (2021-2034)

10.5.4. Rest of LATAM

10.5.4.1. Market Revenue and Forecast, by Drug (2021-2034)

10.5.4.2. Market Revenue and Forecast, by Therapeutic Area (2021-2034)

Chapter 11. Company Profiles

11.1. F. Hoffmann-La Roche AG

11.1.1. Company Overview

11.1.2. Product Offerings

11.1.3. Financial Performance

11.1.4. Recent Initiatives

11.2. GlaxoSmithKline plc.

11.2.1. Company Overview

11.2.2. Product Offerings

11.2.3. Financial Performance

11.2.4. Recent Initiatives

11.3. AbbVie, Inc.

11.3.1. Company Overview

11.3.2. Product Offerings

11.3.3. Financial Performance

11.3.4. Recent Initiatives

11.4. Amgen, Inc.

11.4.1. Company Overview

11.4.2. Product Offerings

11.4.3. Financial Performance

11.4.4. Recent Initiatives

11.5. Merck & Co., Inc.

11.5.1. Company Overview

11.5.2. Product Offerings

11.5.3. Financial Performance

11.5.4. Recent Initiatives

11.6. Alligator Bioscience

11.6.1. Company Overview

11.6.2. Product Offerings

11.6.3. Financial Performance

11.6.4. Recent Initiatives

11.7. UbiVac

11.7.1. Company Overview

11.7.2. Product Offerings

11.7.3. Financial Performance

11.7.4. Recent Initiatives

11.8. Bristol-Myers Squibb

11.8.1. Company Overview

11.8.2. Product Offerings

11.8.3. Financial Performance

11.8.4. Recent Initiatives

11.9. Novartis International AG

11.9.1. Company Overview

11.9.2. Product Offerings

11.9.3. Financial Performance

11.9.4. Recent Initiatives

11.10. AstraZeneca plc

11.10.1. Company Overview

11.10.2. Product Offerings

11.10.3. Financial Performance

11.10.4. Recent Initiatives

Chapter 12. Research Methodology

12.1. Primary Research

12.2. Secondary Research

12.3. Assumptions

Chapter 13. Appendix

13.1. About Us

13.2. Glossary of Terms

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client